Dechert LLP

Dechert LLP‘s capital markets practice is driven in large part by the life sciences and permanent capital vehicle clients, including business development companies (BDCs). The firm has worked on a series of notable equity deals including at-the-market offerings. Washington DC-based Harry Pangas heads the US capital markets group and is noted for his work in the BDC sector, as is Boston’s Thomas Friedmann, who co-heads the permanent capital practice. New York’s David Rosenthal co-leads the life sciences team and has extensive experience in capital markets transactions.